Oncology

Agent found to stop growth and spread of prostate cancer with a common chromosomal abnormality.

ASHP today recognized the work of the late Jerod M. Loeb, Ph.D., a tireless patient safety advocate, with the ASHP Board of Directors Award of Honor. Loeb's widow, Sherri, accepted the award during the opening session of ASHP's Midyear Clinical Meeting in Anaheim, CA. Dr. Loeb passed away in 2013 from metastatic prostate cancer.

Primary ADT associated with decreased survival in localized prostate cancer patients.

According to a new study, a CCR5-blocking drug used to treat HIV may also be able to slow prostate cancer metastasis.

Preliminary evidence indicates that new treatment is both safe and effective.

Pfizer's phase 3 study of its anaplastic lymphoma kinase inhibitor, crizotinib, provides good news for patients with ALK-positive advanced non-small cell lung cancer.

The OTC antacid is being investigated for its potenial to combat colon cancer.

Alcohol use is responsible for an estimated 3.5% of cancers in the United States, but affects the risk of developing some cancers more than others.

Concerns still remain, however, and there is a lack of long-term data.

Study finds African Americans and Hispanics significantly less likely to be treated with radiation.

Therapy extended lives of patients by approximately 5 months.

Increased number of patients moving away from breast conservation surgery in early stages of disease.

Oral drug combination effective in treating newly diagnosed multiple myeloma.

A new liquid drug formulation from Teva Pharmaceutical Industries Ltd. will allow some cancer patients to see their therapy administered faster.

Combination therapy eliminates tumors in more than 70% of mice.

Cyclophosphamide found to improve the success of virus therapy in patients with malignant gliomas.

Next generation drug shows anti-cancer activity in 10 of 11 tumor samples during lab tests.

Research may lead to more effective treatments in the future.

Drugs commonly used to treat osteoporosis may benefit patients with diseases like breast cancer.

Bevacizumab with chemotherapy reduced risk of disease progression by 62% compared with chemotherapy alone.

The FDA today approved a new indication for an oncology drug that significantly reduces ovarian cancer disease progression.

RAND Corporation projects biosimilars to cause an approximately 4% reduction in total US biologic spending from 2014 to 2024.

According to researchers, chemotherapy parity laws ignore the real question of cost versus quality. At the same time, these laws promote anticompetitive practices that affect community oncologists.

Chemotherapy parity laws ignore the real question of cost versus quality. At the same time, they promote anticompetitive practices that affect community oncologists.

Cost of medication causes financial burden for nearly two-thirds of patients.

Researchers determine there may be an opportunity to reduce chemotherapy in pediatric patients with hepatoblastoma.